J R O'Dell. Show Affiliations »
Abstract
Entities: Disease Gene
Mesh: See more » Antibodies, Monoclonal/adverse effectsAntibodies, Monoclonal/immunologyAntibodies, Monoclonal/therapeutic useAntirheumatic Agents/adverse effectsAntirheumatic Agents/immunologyAntirheumatic Agents/therapeutic useArthritis, Rheumatoid/drug therapyArthritis, Rheumatoid/immunologyEtanerceptHumansImmunoglobulin G/adverse effectsImmunoglobulin G/immunologyImmunoglobulin G/therapeutic useInfection Control/methodsInfliximabPatient SelectionPractice Guidelines as TopicReceptors, Tumor Necrosis Factor/immunologyReceptors, Tumor Necrosis Factor/therapeutic useSafetySepsis/chemically inducedSepsis/prevention & controlTreatment OutcomeTumor Necrosis Factor-alpha/adverse effectsTumor Necrosis Factor-alpha/immunologyTumor Necrosis Factor-alpha/therapeutic use
Substances: See more » Antibodies, MonoclonalAntirheumatic AgentsImmunoglobulin GReceptors, Tumor Necrosis FactorTumor Necrosis Factor-alphaInfliximabEtanercept
Year: 2001 PMID: 11393494
Source DB: PubMed Journal: Mayo Clin Proc ISSN: 0025-6196 Impact factor: 7.616